Who: Addex/Indivior
Old Flame Indivior Aids Addex After Being Jilted By J&J
Deal Snapshot: It has been a tough few months for the Swiss company since Johnson & Johnson pulled out of their epilepsy pact but long-time partner Indivior has run to its rescue and will advance a substance use disorder compound.
More from Neurological
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
• By
A decision from the FDA is due by 28 September.
• By
A new “quasi-experimental” study using UK National Health Service data might confirm that GSK’s shingles vaccine helps cut dementia cases.
More from Therapy Areas
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.